Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wiley 2022-04-01
Reeks:Thoracic Cancer
Onderwerpen:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Online toegang:https://doi.org/10.1111/1759-7714.14357
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items